1. Home
  2. SST vs PHIO Comparison

SST vs PHIO Comparison

Compare SST & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo System1 Inc.

SST

System1 Inc.

HOLD

Current Price

$3.49

Market Cap

12.9M

ML Signal

HOLD

Logo Phio Pharmaceuticals Corp.

PHIO

Phio Pharmaceuticals Corp.

HOLD

Current Price

$1.03

Market Cap

12.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SST
PHIO
Founded
2013
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.9M
12.9M
IPO Year
2020
2011

Fundamental Metrics

Financial Performance
Metric
SST
PHIO
Price
$3.49
$1.03
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$10.00
$14.00
AVG Volume (30 Days)
1.3M
177.7K
Earning Date
05-06-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$266,129,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.35
$0.81
52 Week High
$9.30
$4.19

Technical Indicators

Market Signals
Indicator
SST
PHIO
Relative Strength Index (RSI) 64.82 39.62
Support Level $1.63 $0.99
Resistance Level $4.92 $1.14
Average True Range (ATR) 0.58 0.06
MACD 0.25 -0.02
Stochastic Oscillator 57.57 11.54

Price Performance

Historical Comparison
SST
PHIO

About SST System1 Inc.

System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It operate several flagship brands across multiple consumer verticals, including shopping, travel and search, and a customer acquisition and marketing platform powered by Artificial Intelligence and machine learning. The company's segment includes Marketing and Products. It generates maximum revenue from the Marketing segment. Geographically, it operates in United States and Other countries.

About PHIO Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.

Share on Social Networks: